# Clinical Trial Landscape: 01_nsclc_kras_g12c_standard

*Generated: 2026-01-05 06:54:30*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 12

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 1 | 31 | ██████ 31.0% |
| Phase 2 | 24 | ████ 24.0% |
| Phase 3 | 16 | ███ 16.0% |
| Phase 1/Phase 2 | 14 | ██ 14.0% |
| Unknown | 6 | █ 6.0% |
| Not Applicable | 6 | █ 6.0% |
| Phase 2/Phase 3 | 2 |  2.0% |
| Early Phase 1 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 99 (99.0%)
- **Enrolling by invitation**: 1 (1.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| M.D. Anderson Cancer Center | 6 |
| Hoffmann-La Roche | 5 |
| Eli Lilly and Company | 5 |
| Merck Sharp & Dohme LLC | 5 |
| Amgen | 5 |
| Mirati Therapeutics Inc. | 4 |
| National Cancer Institute (NCI) | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| Revolution Medicines, Inc. | 3 |
| SWOG Cancer Research Network | 2 |
| Mayo Clinic | 2 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Thera | 2 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Daiichi Sankyo | 1 |
| Dana-Farber Cancer Institute | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Pembrolizumab | 26 |
| Carboplatin | 18 |
| Pemetrexed | 16 |
| Cisplatin | 13 |
| Adagrasib | 10 |
| Cetuximab | 10 |
| Sotorasib | 9 |
| Paclitaxel | 6 |
| Magnetic Resonance Imaging | 5 |
| Divarasib | 5 |
| Nivolumab | 5 |
| Placebo | 5 |
| Osimertinib | 4 |
| Bevacizumab | 4 |
| Biospecimen Collection | 4 |
| Computed Tomography | 4 |
| Gemcitabine | 4 |
| Questionnaire Administration | 3 |
| Entrectinib | 3 |
| Atezolizumab | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 35 |
| South Korea | 33 |
| France | 30 |
| Japan | 29 |
| Australia | 29 |
| Italy | 28 |
| Taiwan | 26 |
| Netherlands | 23 |
| Germany | 23 |
| Poland | 23 |
| Canada | 22 |
| China | 22 |
| United Kingdom | 21 |
| Brazil | 21 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| NSCLC | manual | 1.0 |
| KRAS G12C NSCLC | manual | 1.0 |
| KRAS G12C non-small cell lung cancer | llm | 0.9 |
| NSCLC KRAS G12C | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung adenocarcinoma | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT06671613](https://clinicaltrials.gov/study/NCT06671613) | Not Applicable | Recruiting | VA Office of Researc... | Evaluating the Impact of Intermitte... |
| [NCT06793215](https://clinicaltrials.gov/study/NCT06793215) | Phase 3 | Recruiting | Hoffmann-La Roche | A Phase III, Randomized, Open-Label... |
| [NCT06712745](https://clinicaltrials.gov/study/NCT06712745) | Early Phase 1 | Recruiting | University of Texas ... | Feasibility Study of Personalized U... |
| [NCT06814496](https://clinicaltrials.gov/study/NCT06814496) | Phase 1/Phase 2 | Recruiting | University of Arizon... | RAdiation comBined With BIspecific ... |
| [NCT07094204](https://clinicaltrials.gov/study/NCT07094204) | Phase 1 | Recruiting | Astellas Pharma Inc | A Phase 1 Study of ASP5834 in Parti... |
| [NCT06997497](https://clinicaltrials.gov/study/NCT06997497) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Open-label, ... |
| [NCT06973564](https://clinicaltrials.gov/study/NCT06973564) | Phase 1/Phase 2 | Recruiting | Jacobio Pharmaceutic... | A Phase 1/2a, Multicenter, Open-lab... |
| [NCT06881784](https://clinicaltrials.gov/study/NCT06881784) | Phase 3 | Recruiting | Revolution Medicines... | RASolve 301: Phase 3 Multicenter, O... |
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Phase 3 | Recruiting | Mirati Therapeutics ... | A Randomized, Double-Blind, Phase 3... |
| [NCT06401330](https://clinicaltrials.gov/study/NCT06401330) | Phase 3 | Recruiting | Children's Oncology ... | Risk Adapted Treatment of Unilatera... |
| [NCT06917079](https://clinicaltrials.gov/study/NCT06917079) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06890598](https://clinicaltrials.gov/study/NCT06890598) | Phase 3 | Recruiting | Eli Lilly and Compan... | A Phase 3, Multicenter, Double-Blin... |
| [NCT06385262](https://clinicaltrials.gov/study/NCT06385262) | Phase 2 | Recruiting | Duke University | Safety, Efficacy, and Tumor Immune ... |
| [NCT06804824](https://clinicaltrials.gov/study/NCT06804824) | Phase 1 | Recruiting | Vividion Therapeutic... | A Phase 1/1b, Open-Label, Multicent... |
| [NCT06720987](https://clinicaltrials.gov/study/NCT06720987) | Phase 1 | Recruiting | Kumquat Biosciences ... | A Phase 1/1b, Open-label, Multicent... |
| [NCT06807619](https://clinicaltrials.gov/study/NCT06807619) | Phase 1 | Recruiting | Memorial Sloan Kette... | BrainMet ADePPT (Anticancer Drug Pe... |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Phase 2 | Recruiting | Jazz Pharmaceuticals | A Phase 2, Open-label, Multicenter ... |
| [NCT05669846](https://clinicaltrials.gov/study/NCT05669846) | Phase 2 | Recruiting | Diwakar Davar | Phase II Feasibility Study of Healt... |
| [NCT06593522](https://clinicaltrials.gov/study/NCT06593522) | Phase 2 | Recruiting | Amgen | A Phase 2 Study Evaluating the Effi... |
| [NCT06566443](https://clinicaltrials.gov/study/NCT06566443) | Phase 1 | Recruiting | The Methodist Hospit... | Phase I Trial Evaluating the Safety... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06607185](https://clinicaltrials.gov/study/NCT06607185) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Phase 1a/1b Study of the Pan-KRAS... |
| [NCT06561386](https://clinicaltrials.gov/study/NCT06561386) | Phase 3 | Recruiting | Bristol-Myers Squibb | A Phase 3, Randomized, Open-label S... |
| [NCT06333951](https://clinicaltrials.gov/study/NCT06333951) | Phase 1 | Recruiting | Amgen | A Phase 1b Study Evaluating the Saf... |
| [NCT06582771](https://clinicaltrials.gov/study/NCT06582771) | Phase 2 | Recruiting | Memorial Sloan Kette... | A Phase 2 Study of First-line Sotor... |
| [NCT06412198](https://clinicaltrials.gov/study/NCT06412198) | Phase 1/Phase 2 | Recruiting | M.D. Anderson Cancer... | A Multicenter Phase 1b/2 Study of A... |
| [NCT06248606](https://clinicaltrials.gov/study/NCT06248606) | Phase 2 | Recruiting | Ryan Gentzler, MD | Phase II Study of Adagrasib + Stere... |
| [NCT06545331](https://clinicaltrials.gov/study/NCT06545331) | Phase 1 | Recruiting | Exelixis | A Dose-Escalation and Expansion Stu... |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Phase 2 | Recruiting | National Cancer Inst... | A Randomized Phase II Study of AMG ... |
| [NCT06252129](https://clinicaltrials.gov/study/NCT06252129) | Not Applicable | Recruiting | Brigham and Women's ... | Maximizing Lymph Node Dissection on... |
| [NCT06252649](https://clinicaltrials.gov/study/NCT06252649) | Phase 3 | Recruiting | Amgen | Phase 3 Multicenter, Randomized, Op... |
| [NCT06447662](https://clinicaltrials.gov/study/NCT06447662) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-Label Study of PF-07... |
| [NCT06422143](https://clinicaltrials.gov/study/NCT06422143) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | Phase 3 Study of Pembrolizumab in C... |
| [NCT06345729](https://clinicaltrials.gov/study/NCT06345729) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Randomized, Double-blind... |
| [NCT06343402](https://clinicaltrials.gov/study/NCT06343402) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06400472](https://clinicaltrials.gov/study/NCT06400472) | Phase 1 | Recruiting | Eli Lilly and Compan... | A First-in-Human, Phase 1a/1b Trial... |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Phase 2 | Recruiting | Mayo Clinic | Pilot Single-Arm, Pragmatic Trial o... |
| [NCT06249282](https://clinicaltrials.gov/study/NCT06249282) | Phase 1 | Recruiting | City of Hope Medical... | A Phase I Clinical Trial of Carfilz... |
| [NCT06124118](https://clinicaltrials.gov/study/NCT06124118) | Phase 1 | Recruiting | University of Utah | A Feasibility Study to Evaluate the... |
| [NCT06312137](https://clinicaltrials.gov/study/NCT06312137) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3 Randomized Open-Label Stu... |
| [NCT06253871](https://clinicaltrials.gov/study/NCT06253871) | Phase 1 | Recruiting | Iambic Therapeutics,... | A Phase 1/1b Study of IAM1363 in Pa... |
| [NCT06225804](https://clinicaltrials.gov/study/NCT06225804) | Phase 1 | Recruiting | Abbisko Therapeutics... | A Phase 1, Open-Label Study of ABSK... |
| [NCT06117774](https://clinicaltrials.gov/study/NCT06117774) | Phase 3 | Recruiting | Amgen | A Phase 3, Randomized, Double-blind... |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Phase 2 | Recruiting | Mirati Therapeutics ... | A Randomized Study of Two Dosing Re... |
| [NCT06244771](https://clinicaltrials.gov/study/NCT06244771) | Phase 1/Phase 2 | Recruiting | Frontier Medicines C... | An Open-Label, Phase 1/2 Dose Escal... |
| [NCT06130254](https://clinicaltrials.gov/study/NCT06130254) | Phase 1 | Recruiting | M.D. Anderson Cancer... | Phase Ib Trial of the KRAS G12C Inh... |
| [NCT06162221](https://clinicaltrials.gov/study/NCT06162221) | Phase 1/Phase 2 | Recruiting | Revolution Medicines... | A Platform Study of RAS(ON) Inhibit... |
| [NCT06119581](https://clinicaltrials.gov/study/NCT06119581) | Phase 3 | Recruiting | Eli Lilly and Compan... | SUNRAY-01, A Global Pivotal Study i... |
| [NCT05920356](https://clinicaltrials.gov/study/NCT05920356) | Phase 3 | Recruiting | Amgen | A Phase 3, Multicenter, Randomized,... |
| [NCT06128551](https://clinicaltrials.gov/study/NCT06128551) | Phase 1 | Recruiting | Revolution Medicines... | Phase 1b, Multicenter, Open-Label, ... |

*... and 50 more trials (see trials.csv for full list)*
